Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - paspalum notatum, quantity: 1 ml/ml (equivalent: paspalum notatum, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 20000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense pollen - unii:65m88rw2eg), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), agrostis gigantea pollen (unii: hu8v6e7hoa) (agrostis gigantea pollen - unii:hu8v6e7hoa), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y) - phleum pratense pollen 20000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - phleum pratense, quantity: 1 ml/ml (equivalent: phleum pratense, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - lolium perenne, quantity: 1 ml/ml (equivalent: lolium perenne, qty 50 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Canada - English - Health Canada

greer laboratories inc - standardized kentucky blue/june grass pollen; standardized orchard grass pollen; standardized redtop grass pollen; standardized timothy grass pollen - solution - 10000unit; 10000unit; 10000unit; 10000unit - standardized kentucky blue/june grass pollen 10000unit; standardized orchard grass pollen 10000unit; standardized redtop grass pollen 10000unit; standardized timothy grass pollen 10000unit - allergenic extracts

Canada - English - Health Canada

greer laboratories inc - standardized kentucky blue/june grass pollen; standardized orchard grass pollen; standardized redtop grass pollen; standardized timothy grass pollen - solution - 100000unit; 100000unit; 100000unit; 100000unit - standardized kentucky blue/june grass pollen 100000unit; standardized orchard grass pollen 100000unit; standardized redtop grass pollen 100000unit; standardized timothy grass pollen 100000unit - allergenic extracts

United States - English - NLM (National Library of Medicine)

antigen laboratories, inc. - ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), sorghum halepense pollen (unii: 577va5b4hp) (sorghum halepense pollen - unii:577va5b4hp), quercus alba pollen (unii: z4y9zsv4kk) (quercus alba pollen - unii:z4y9zsv4kk), carya alba pollen (unii: g2a764t54b) (carya alba pollen - unii:g - ambrosia artemisiifolia pollen 10000 [au] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

New Zealand - English - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - grass pollen extract 300 ir - sublingual tablet - active: grass pollen extract 300 ir excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Malta - English - Medicines Authority

stallergenes s.a. 6 rue alexis de tocqueville, 92160 antony, france - grass pollen, allergen extract - sublingual tablet - grass pollen allergen extract - allergens